自身免疫性肝炎与原发性胆汁性胆管炎:IL12通路遗传风险与共病聚集
研究评估27种自身免疫病中IL12信号通路的遗传支持,发现IL12A上游罕见变异显著增加AIH、PBC、SSc、SjD、SLE和MS风险,纯合携带者终生风险增加6倍。AIH、PBC、SSc、SjD和SLE五种疾病相互强烈共现,提示共享病因并可能对相同靶向治疗应答。
要点
- IL12A上游罕见变异与AIH、PBC、SSc、SjD、SLE和MS风险显著相关。
- AIH、PBC、SSc、SjD和SLE五种疾病相互强烈共现,提示共享病因。
- IL12通路遗传关联支持这些疾病可能对相同靶向治疗应答。
核心结论
- AIH、PBC、SSc、SjD和SLE构成一个独特自身免疫病子集,共享IL12通路遗传关联和强烈共现,提示共享病因并可能对相同靶向治疗应答。
研究设计与样本
- 研究评估27种疾病中IL12信号通路的遗传支持,并进行了6种疾病的流行病学共现分析。
主要发现
- IL12A上游罕见变异增加AIH风险(每等位基因OR=2.98,p=3×10^-9)、PBC风险(OR=2.80,p=2×10^-8)、SSc风险(OR=2.64,p=2×10^-11)、SjD风险(OR=1.94,p=10^-11)、SLE风险(OR=1.83,p=5×10^-10)和MS风险(OR=1.79,p=10^-11)。
- 纯合携带者发生至少一种上述疾病的终生风险增加6倍(OR=5.73,p=0.003)。
- IL12A下游非编码变异(与较低基因表达相关)对6种疾病中的5种具有保护作用。
- IL12RB2内含子变异(与较高基因表达相关)增加全部6种疾病风险;IL12RB2罕见预测功能丧失或错义变异杂合携带者SLE风险降低18%(OR=0.82,p=2×10^-5)。
- IL23信号通路与这些疾病无关;AIH、PBC、SSc、SjD和SLE五种疾病相互强烈共现。
关键数值与推荐
- AIH每等位基因OR=2.98(p=3×10^-9),PBC OR=2.80(p=2×10^-8),SSc OR=2.64(p=2×10^-11),SjD OR=1.94(p=10^-11),SLE OR=1.83(p=5×10^-10),MS OR=1.79(p=10^-11)。
- 纯合携带者终生风险增加6倍(OR=5.73,p=0.003)。
- IL12RB2罕见预测功能丧失或错义变异杂合携带者SLE风险降低18%(OR=0.82,p=2×10^-5)。
临床怎么用
- 对AIH和PBC患者应关注SSc、SjD和SLE的共病筛查,因其相互强烈共现。
- IL12通路遗传关联提示这些疾病可能对相同靶向治疗应答,为治疗选择提供依据。
局限性
- 研究未报告样本量、研究人群来源和遗传分析的具体方法学细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Distinct autoimmune diseases can share symptoms and autoantibodies, but the molecular pathways underlying this shared etiology remain poorly understood. We assessed genetic support for IL12 signaling across 27 diseases. APPROACH AND RESULTS: We identified a rare variant upstream of IL12A with large risk-increasing effects on autoimmune hepatitis [AIH; per-allele odds ratio (OR)=2.98, p =3×10 -9 ], primary biliary cholangitis (PBC; OR=2.80, p =2×10 -8 ), systemic sclerosis (SSc; OR=2.64, p =2×10 -11 ), Sjogren's disease (SjD; OR=1.94, p =10 -11 ), systemic lupus erythematosus (SLE; OR=1.83, p =5×10 -10 ) and multiple sclerosis (OR=1.79, p =10 -11 ). Lifetime risk for developing at least one of these conditions increased 6-fold in homozygote carriers (OR=5.73, p =0.003). We then evaluated genetic support for all 4 IL12 signaling genes and found that: (i) a non-coding variant downstream of IL12A (linked to lower gene expression) protected against 5 of the 6 diseases; (ii) an intronic variant in IL12RB2 (linked to higher gene expression) increased risk of all 6 diseases; and (iii) heterozygote carriers of rare predicted loss-of-function or missense variants in IL12RB2 had 18% lower odds of SLE (OR=0.82, p =2×10 -5 ). IL23 signaling, which shares ligand and receptor subunits with IL12, was not associated with these conditions. In epidemiologic analyses of co-prevalence, 5 of the 6 diseases strongly co-occurred with each other: AIH, PBC, SSc, SjD and SLE. CONCLUSIONS: AIH, PBC, SSc, SjD and SLE represent a distinct subset of autoimmune diseases that share genetic associations with the IL12 pathway, as well as profound co-prevalence, suggesting they may have a shared etiology and may respond to the same targeted therapeutic intervention(s).
引用
- Nakka P, Hobbs BD, Sidore C, et al. Autoimmune hepatitis and primary biliary cholangitis are among a subset of autoimmune diseases defined by profound co-prevalence and genetic risk association with the IL12 pathway. Hepatology. 2026. PMID: 42868031. doi:10.1097/HEP.0000000000001819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。